IP Seminar on Repurposed Drugs - Is Robust Exclusivity Possible?
Is it still possible to reach commercial success with a repurposed drug? Mike Nelson and Marie-Louise Jardle from HGF will explore the options available for providing exclusivity for repurposed drugs and assess the strengths and weaknesses of so called “second medical use” patents, and what practical measures can be implemented to maximise exclusivity.
Thursday 21st June, 6pm
Der Teufelhof Basel, Switzerland
It is a fact of life that many drugs fail in clinical trials. However, failure in the primary indication does not mean the drug is dead. There are many examples of failed drugs, as well as approved drug products, that have been successfully “repurposed” for a different indication.
Repurposing can be an attractive option because there is already some knowledge about the safety and biological effects of the drug, which can significantly reduce development time, costs and risks for the new indication. However, successfully protecting the new indication with patents can present challenges.